Elraglusib
- Generic Name
- Elraglusib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H13FN2O5
- CAS Number
- 1034895-42-5
- Unique Ingredient Identifier
- ND1SOF0DLU
- Background
Elraglusib is under investigation in clinical trial NCT04218071 (Actuate 1901: 9-ING-41 in Myelofibrosis).
- Associated Conditions
- -
- Associated Therapies
- -
Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Pancreatic Ductal Adenocarcinoma Treatment
Actuate Therapeutics' elraglusib, a GSK-3β inhibitor, received EMA Orphan Medicinal Product Designation for pancreatic ductal adenocarcinoma (PDAC) treatment. Positive Phase 2 trial interim results showed significant clinical benefits, aiming to expedite elraglusib's development as a novel mPDAC treatment.
Related Clinical Trials:
EMA grants orphan drug designation to Actuate's cancer drug
Actuate Therapeutics' drug elraglusib received EMA's Orphan Medicinal Product Designation for treating pancreatic ductal adenocarcinoma, showing promise in Phase 2 trials with improved survival rates. The company plans to report topline data in 2025 and has also gained FDA's rare pediatric disease designation for Ewing sarcoma treatment.
Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib in Pancreatic Cancer Treatment
Actuate Therapeutics' elraglusib, a GSK-3β inhibitor, received EMA Orphan Medicinal Product Designation for treating pancreatic cancer. Positive Phase 2 trial results show significant clinical benefits, aiming to expedite elraglusib's development as a novel treatment for metastatic pancreatic cancer.
Related Clinical Trials:
Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib in Treating Pancreatic Ductal Adenocarcinoma
Actuate Therapeutics' elraglusib, a GSK-3β inhibitor, received EMA Orphan Medicinal Product Designation for treating pancreatic ductal adenocarcinoma (PDAC). Positive Phase 2 trial results showed significant clinical benefits, aiming to expedite elraglusib's development as a novel treatment for metastatic PDAC.
Related Clinical Trials:
Actuate sees 37% cut in risk of death in Phase II pancreatic cancer trial
Actuate Therapeutics' elraglusib reduced death risk by 37% in a Phase I/II metastatic pancreatic cancer trial, doubling one-year survival rate to 43.6% in the treatment arm vs 22.5% in the control arm. The company plans a Phase III study based on these encouraging results.
Related Clinical Trials:
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath